Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 6 | 2 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Rett Syndrome Overview | 9 | 1 |
| Therapeutics Development | 10 | 2 |
| Pipeline Products for Rett Syndrome Overview | 10 | 1 |
| Pipeline Products for Rett Syndrome Comparative Analysis | 11 | 1 |
| Rett Syndrome Therapeutics under Development by Companies | 12 | 2 |
| Rett Syndrome Therapeutics under Investigation by Universities/Institutes | 14 | 1 |
| Rett Syndrome Pipeline Products Glance | 15 | 4 |
| Late Stage Products | 15 | 1 |
| Clinical Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Unknown Stage Products | 18 | 1 |
| Rett Syndrome Products under Development by Companies | 19 | 1 |
| Rett Syndrome Products under Investigation by Universities/Institutes | 20 | 1 |
| Rett Syndrome Companies Involved in Therapeutics Development | 21 | 17 |
| Anavex Life Sciences Corp. | 21 | 1 |
| ArmaGen Inc. | 22 | 1 |
| Edison Pharmaceuticals, Inc. | 23 | 1 |
| Eloxx Pharmaceuticals, Ltd. | 24 | 1 |
| GW Pharmaceuticals Plc | 25 | 1 |
| Mitochon Pharmaceuticals, Inc. | 26 | 1 |
| Mitsubishi Tanabe Pharma Corporation | 27 | 1 |
| Neuren Pharmaceuticals Limited | 28 | 1 |
| Neurolixis Inc. | 29 | 1 |
| Newron Pharmaceuticals S.p.A. | 30 | 1 |
| OPKO Health, Inc. | 31 | 1 |
| Oryzon Genomics SA | 32 | 1 |
| PharmatrophiX, Inc. | 33 | 1 |
| Raptor Pharmaceutical Corp. | 34 | 1 |
| Recursion Pharmaceuticals, LLC | 35 | 1 |
| Sage Therapeutics, Inc. | 36 | 1 |
| Ultragenyx Pharmaceutical Inc. | 37 | 1 |
| Rett Syndrome Therapeutics Assessment | 38 | 9 |
| Assessment by Monotherapy Products | 38 | 1 |
| Assessment by Target | 39 | 2 |
| Assessment by Mechanism of Action | 41 | 2 |
| Assessment by Route of Administration | 43 | 2 |
| Assessment by Molecule Type | 45 | 2 |
| Drug Profiles | 47 | 63 |
| amlexanox Drug Profile | 47 | 1 |
| ANAVEX-273 Drug Profile | 48 | 9 |
| Bryostatin-1 Drug Profile | 57 | 4 |
| CPT-157633 Drug Profile | 61 | 1 |
| cysteamine DR Drug Profile | 62 | 8 |
| desipramine hydrochloride Drug Profile | 70 | 1 |
| ELX-02 Drug Profile | 71 | 1 |
| fingolimod hydrochloride Drug Profile | 72 | 6 |
| Gene therapy to Activate MECP2 for Rett Syndrome Drug Profile | 78 | 1 |
| LM-22A4 Drug Profile | 79 | 1 |
| MP-101 Drug Profile | 80 | 1 |
| NLX-101 Drug Profile | 81 | 1 |
| Oligonucleotide For Rett Syndrome Drug Profile | 82 | 1 |
| ORY-2001 Drug Profile | 83 | 2 |
| Recombinant Protein for Rett Syndrome Drug Profile | 85 | 1 |
| REV-003 Drug Profile | 86 | 1 |
| SAGE-217 Drug Profile | 87 | 2 |
| sarizotan hydrochloride Drug Profile | 89 | 3 |
| Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders Drug Profile | 92 | 1 |
| Small Molecules for Rett Syndrome Drug Profile | 93 | 1 |
| Small Molecules to Agonize Cannabinoid Receptor 2 for Fragile X Syndrome, Pervasive Developmental Disorder and Rett Syndrome Drug Profile | 94 | 1 |
| trofinetide Drug Profile | 95 | 6 |
| UX-007 Drug Profile | 101 | 5 |
| vatiquinone Drug Profile | 106 | 4 |
| Rett Syndrome Dormant Projects | 110 | 1 |
| Rett Syndrome Product Development Milestones | 111 | 10 |
| Featured News &Press Releases | 111 | 1 |
| Jun 24, 2016: Neuren presents at the Rettsyndrome.org 2016 Research Symposium | 111 | 1 |
| Jun 22, 2016: Neuren receives grant of new Australian patent for trofinetide to treat Autism Spectrum Disorders | 111 | 1 |
| Jun 06, 2016: Anavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X Autism-Related Disorders | 112 | 1 |
| May 20, 2016: Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX 2-73 for the Treatment of Rett Syndrome | 113 | 1 |
| May 17, 2016: Mitochon Pharmaceuticals Raises $1.6M for Clinical Stage Development | 113 | 1 |
| Apr 07, 2016: First subject commences Neuren s pediatric Rett syndrome Phase 2 trial | 113 | 1 |
| Feb 25, 2016: Anavex Presents Preclinical Results of ANAVEX 2-73 in Rett Syndrome | 114 | 1 |
| Oct 13, 2015: Rettsyndrome.org confirms financial support for Neuren s clinical trials of trofinetide | 115 | 1 |
| Oct 12, 2015: Neuren receives Notice of Allowance for new US patent covering the use of trofinetide to treat Rett syndrome | 116 | 1 |
| Aug 14, 2015: trofinetide confirmed as the International Nonproprietary Name for Neuren s NNZ-2566 | 116 | 1 |
| Aug 13, 2015: Neuren confirms orphan drug designation in Europe for Rett syndrome and Fragile X syndrome | 116 | 1 |
| Jul 29, 2015: Neuren reports progress in orphan drug programs | 117 | 1 |
| Nov 12, 2014: Neuren s NNZ-2566 successful In Demonstrating Clinical Benefit In Rett syndrome Phase 2 trial | 118 | 1 |
| Dec 24, 2012: Neuren Pharma Receives FDA Approval For Phase II trial Of NNZ-2566 In Rett Syndrome | 119 | 1 |
| May 17, 2012: Neuren Holds Pre-IND Meeting On Proposed Rett Syndrome Clinical Trials With FDA | 120 | 1 |
| Appendix | 121 | 2 |
| Methodology | 121 | 1 |
| Coverage | 121 | 1 |
| Secondary Research | 121 | 1 |
| Primary Research | 121 | 1 |
| Expert Panel Validation | 121 | 1 |
| Contact Us | 121 | 1 |
| Disclaimer | 122 | 1 |